NCT05681273View on ClinicalTrials.gov

Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 17, 2023

Primary Completion Date

March 21, 2023

Study Completion Date

March 21, 2023

Conditions
T2DM
Interventions
DRUG

Chiglitazar

Chiglitazar 48mg

DRUG

Empagliflozin

Empagliflozin 10mg

DRUG

Atorvastatin

Atorvastatin 20mg

DRUG

Valsartan

Valsartan 160mg

Trial Locations (1)

Unknown

Zhongshan hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY

NCT05681273 - Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects. | Biotech Hunter | Biotech Hunter